About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York State | 17,167 Studies Near You | Clareo Health

Clinical Trials LocationsNew York State

Clinical Trials in New York State

Discover 17,167 clinical trials near New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 15241-15260 of 17,167 trials

COMPLETEDPhase 1/239 miles

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

NCT01308424

The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.

Oral Herpes Simplex

Beech Tree Labs, Inc.171 participantsStarted Jan 2011

Lexington, Kentucky, United States • Buffalo, New York, United States • Norwich, New York, United States +1 more locations

TERMINATEDPhase 486 miles

Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)

NCT00206856

To determine the clinical utility of using the Triage® BNP Test to guide therapy in outpatients with heart failure

Abbott RDx Cardiometabolic720 participantsStarted Jul 2003

Scottsdale, Arizona, United States • San Diego, California, United States • San Francisco, California, United States +26 more locations

Find Trials by Condition in New York State

Breast Cancerin New York State Lung Cancerin New York State Prostate Cancerin New York State Colorectal Cancerin New York State Melanomain New York State Leukemiain New York State Lymphomain New York State Pancreatic Cancerin New York State Ovarian Cancerin New York State Brain Cancerin New York State

Data from ClinicalTrials.govTerms

COMPLETEDPhase 291 miles

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737

The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.

Type 2 Diabetes Mellitus

Akros Pharma Inc.325 participantsStarted Sep 2012

Birmingham, Alabama, United States • Dothan, Alabama, United States • Huntsville, Alabama, United States +76 more locations

COMPLETEDPhase 2100 miles

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

NCT00583830

The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).

Non Small Cell Lung Cancer

Human Genome Sciences Inc.111 participantsStarted Jan 2007

Birmingham, Alabama, United States • Rancho Mirage, California, United States • Aurora, Colorado, United States +30 more locations

COMPLETEDPhase 1107 miles

Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis

NCT01199887

This is an open label, Phase One, multicenter study, designed to evaluate the safety, tolerability, to explore the biologic effects, and to explore the clinical effects of the following doses of IW001: 0.1mg/day, 0.5 mg/day, and 1.0 mg/day, when administered once a day orally for 24 weeks in patients with IPF.

Idiopathic Pulmonary Fibrosis

ImmuneWorks30 participantsStarted Sep 2010

Birmingham, Alabama, United States • Miami, Florida, United States • Chicago, Illinois, United States +8 more locations

COMPLETEDPhase 3107 miles

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

NCT00411385

This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 2/3 who are IFNa treatment naive.

Chronic Hepatitis C

Human Genome Sciences Inc.933 participantsStarted Feb 2007

Phoenix, Arizona, United States • La Jolla, California, United States • San Francisco, California, United States +156 more locations

COMPLETEDPhase 3108 miles

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

NCT01077960

In Serono Study 24380, the antecedent protocol to Study 25373, patients were randomly assigned in a 3.0-to-1.0 ratio to Groups A and B. All patients in Group A received recombinant human growth hormone (Serostim®) 4 mg daily (the "induction" phase) for the first 12 weeks, and then were re-randomized to receive either placebo or Serostim 2 mg on alternate days (roughly equivalent to 1 mg daily) during Weeks 12-36 (the "maintenance" phase). All patients in Group B initially received placebo from baseline to Week 24, and then received Serostim® 4 mg daily from Weeks 24 to 36 (Grunfeld, 2007). In the follow-up Study 25373, any subject who was enrolled in Serono Study 24380 and was assigned to Group A, who fully completed all study visits without a major protocol violation, was eligible to enroll to receive re-treatment with Serostim at a dose of 4 mg daily for 12 weeks. During study 25373, safety was monitored by recording of adverse events and measurement of urinalysis and laboratory blood tests to assess fasting glucose, fasting insulin, and routine biochemistry and hematology parameters. At Week 12 or at the time of study termination, subjects underwent re-assessment of body composition via anthropometry measurements and dual photon absorptiometry (DXA) scanning. In addition, at study termination, measurements of insulin-like growth factor I (IGF-I), insulin-like growth binding protein 3 (IGFBP-3), fasting lipid profile, and oral glucose tolerance testing were obtained.

Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

EMD Serono126 participantsStarted Feb 2005

Birmingham, Alabama, United States • Los Angeles, California, United States • Palm Beach, California, United States +23 more locations

COMPLETEDPhase 3112 miles

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

NCT00109733

The primary objective is to evaluate the efficacy and safety of two different dose regimens of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during the transition phase from childhood to adulthood.

Childhood-onset Growth Hormone DeficiencyPituitary Dwarfism

EMD Serono31 participantsStarted Jan 2005

Orange, California, United States • Jacksonville, Florida, United States • Orlando, Florida, United States +6 more locations

COMPLETEDPhase 2112 miles

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

NCT00094848

The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).

Lymphoma, Non-Hodgkin

Human Genome Sciences Inc.Started Jun 2004

Rochester, Minnesota, United States • Omaha, Nebraska, United States • Buffalo, New York, United States +4 more locations

COMPLETED112 miles

Case-Control Viramune (Nevirapine) Toxicogenomics Study

NCT00310843

Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.

Boehringer Ingelheim889 participantsStarted Feb 2006

Birmingham, Alabama, United States • Denver, Colorado, United States • Baltimore, Connecticut, United States +99 more locations

TERMINATEDPhase 3112 miles

An Open Label Extension Study in Subjects With Fragile X Syndrome

NCT01555333

This study will enroll subjects who have completed Protocols 209FX301, 209FX302, or are currently participating in Protocol 2202 into a long-term study in which all subjects will receive active drug (arbaclofen).

Fragile X Syndrome

Seaside Therapeutics, Inc.357 participantsStarted Nov 2011

Phoenix, Arizona, United States • Long Beach, California, United States • Sacramento, California, United States +20 more locations

TERMINATEDPhase 3112 miles

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

NCT01706523

This is an open-label extension protocol that will provide necessary data on the safety, tolerability, pharmacokinetics and efficacy of STX209 among subjects with ASD.

Autism Spectrum Disorders

Seaside Therapeutics, Inc.165 participantsStarted Nov 2011

Phoenix, Arizona, United States • Los Angeles, California, United States • Sacramento, California, United States +22 more locations

TERMINATEDPhase 2116 miles

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

NCT00732940

The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.

Systemic Lupus Erythematosus

Human Genome Sciences Inc.56 participantsStarted Oct 2008

Birmingham, Alabama, United States • Long Beach, California, United States • Tampa, Florida, United States +8 more locations

COMPLETEDPhase 3118 miles

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

NCT00336492

The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.

Ulcerative Colitis

Centocor, Inc.60 participantsStarted Sep 2006

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +24 more locations

COMPLETED118 miles

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

NCT00823368

The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22001 will be offered participation in 22001A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.

Fragile X Syndrome

Seaside Therapeutics, Inc.Started Jan 2009

Phoenix, Arizona, United States • Los Angeles, California, United States • Sacramento, California, United States +8 more locations

COMPLETEDNA199 miles

Primary Care Physicians' Use of Stop-Smoking Plans to Help Patients Who Are Smokers

NCT00227786

RATIONALE: Stop-smoking plans suggested by physicians may help patients quit smoking. Studying how physicians give stop-smoking treatment as family doctors may increase the chance of smokers receiving such treatment. PURPOSE: This randomized clinical trial is studying physicians' practice patterns to see if regular feedback to the physician increases the chance of adult smokers receiving stop-smoking treatment.

Tobacco Use DisorderUnspecified Adult Solid Tumor, Protocol Specific

Kaiser Permanente344 participantsStarted Jan 2003

Aurora, Colorado, United States • Honolulu, Hawaii, United States • Boston, Massachusetts, United States +2 more locations

TERMINATEDPhase 1/2199 miles

Tolerability Study of Xerecept® in Pediatric Patients

NCT01369121

This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.

Brain EdemaBrain Tumor

Celtic Pharma Development Services15 participantsStarted Jun 2010

Chicago, Illinois, United States • Boston, Massachusetts, United States

COMPLETEDPhase 2199 miles

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

NCT00153985

The purpose of this study is to determine if treatment with reduced-dose busulfex, fludarabine and alemtuzumab (CAMPATH) followed by sten cell infusion will allow for donor stem cells to grow in patients with hemoglobinopathies bone marrow and restore circulating blood counts. In addition the incidence and severity of side effects and of graft vs. host disease (GVHD) will be monitored.

HemoglobinopathiesSickle Cell DiseaseThalassemia

Dana-Farber Cancer Institute2 participantsStarted Mar 2004

Atlanta, Georgia, United States • Shreveport, Louisiana, United States • Boston, Massachusetts, United States +3 more locations

TERMINATEDPhase 2241 miles

Study on Interleukin-7 (CYT107) in HIV Patients

NCT01190111

This study was designed to evaluate the pharmacokinetics of 20µg/kg/week of Interleukin-7 (CYT107), the biological activity and safety of repeated cycles of CYT107, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months.

Cytheris SA23 participantsStarted Jan 2010

Miami, Florida, United States • Bethesda, Maryland, United States • Cleveland, Ohio, United States +1 more locations

COMPLETEDPhase 2607 miles

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00064051

RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving gemcitabine together with 3-AP works in treating patients with unresectable or metastatic pancreatic cancer.

Pancreatic Cancer

Vion PharmaceuticalsStarted Jan 2003

Chicago, Illinois, United States • Indianapolis, Indiana, United States • Minneapolis, Minnesota, United States +4 more locations

PreviousPage 763 of 859Next

Diabetes

in New York State

Heart Diseasein New York State